{"id":517004,"date":"2021-07-23T08:03:02","date_gmt":"2021-07-23T12:03:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/"},"modified":"2021-07-23T08:03:02","modified_gmt":"2021-07-23T12:03:02","slug":"cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/","title":{"rendered":"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection<\/b><\/p>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer\u2019s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection.\n<\/p>\n<p>\n\u201cThere continues to be a large unmet need for coronavirus treatment. The target of COR803 is highly conserved across variants and among coronaviruses in general, therefore it is expected to address both current and future coronavirus strains, including the delta variant of SARS-CoV-2,\u201d said Casey Lynch, Cortexyme\u2019s chief executive officer, co-founder, and chair. \u201cWe have selected COR803 based on compelling data to support its development as a potential therapy that could be prescribed at the first sign of infection or after known exposures without requiring patients to be hospitalized, as well as for those in critical care. The novel characteristics of COR803 reflect the breadth and capabilities of our proprietary research and development as Cortexyme continues to apply our innovative science to areas of high clinical need.\u201d\n<\/p>\n<p>\nCOR803 is a novel patent-pending small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition. 3CLpro, or Mpro, is a validated antiviral drug target shown to be essential in viral replication of SARS-CoV-2. COR803 has beneficial properties over other COVID-19 therapeutics and 3CLpro inhibitors in development including:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nCovalent irreversible binding of the viral 3CLpro enzyme;\n<\/li>\n<li>\nHigh potency: Antiviral EC90 of 30 nM in human lung cell viral replication assays;\n<\/li>\n<li>\nHighly selective for 3CLpro versus other cellular proteases including Cathepsin L; and\n<\/li>\n<li>\nExcellent systemic exposure utilizing intranasal or subcutaneous administration, allowing for clinical use in multiple settings such as outpatient and inpatient.\n<\/li>\n<\/ul>\n<p><b>About Cortexyme <\/b><\/p>\n<p>\nCortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer\u2019s and other degenerative diseases. The company is advancing its disease-modifying pivotal GAIN Trial in mild to moderate Alzheimer&#8217;s disease with top-line data expected in the fourth quarter of 2021, in addition to growing a proprietary pipeline of first-in-class small molecule therapeutics for Parkinson\u2019s disease, periodontitis, and other diseases with high unmet clinical need. Cortexyme\u2019s lead program targets a specific, infectious pathogen called <i>P. gingivalis<\/i> found in the brain and other organs and tied to degeneration and inflammation in humans and animal models. The company\u2019s causation evidence for Alzheimer\u2019s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cortexyme.com&amp;esheet=52464871&amp;newsitemid=20210723005073&amp;lan=en-US&amp;anchor=www.cortexyme.com&amp;index=1&amp;md5=d81dec842462e7c78d7123e5336f8048\">www.cortexyme.com<\/a> or follow @Cortexyme on Twitter.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nStatements in this news release contain \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201coutlook,\u201d \u201cforecast,\u201d or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our business plans, strategy, timeline, prospects, and milestone expectations; the characteristics and potential benefits of COR803, including for the treatment of coronavirus infections, the timing and success of the company\u2019s clinical trials and related data; the potential of atuzaginstat to treat Alzheimer\u2019s disease, periodontal disease, and other potential indications; the timing of announcements and updates relating to its clinical trials and related data; the potential therapeutic benefits, safety and efficacy of the company\u2019s product candidate or library of compounds; and statements about its ability to obtain, and the timing relating to, regulatory submissions and approvals with respect to the company\u2019s drug product candidate. Forward-looking statements are based on Cortexyme\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled \u201cRisk Factors\u201d in Cortexyme\u2019s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2021, its Quarterly Report on Form 10-Q filed with the SEC on May 6, 2021, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210723005073\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210723005073\/en\/<\/a><\/span><\/p>\n<p><b>Cortexyme Contact:<br \/>\n<\/b><br \/>Stacy Roughan<br \/>\n<br \/>Cortexyme, Inc.<br \/>\n<br \/>Vice President, Corporate Communications &amp; Investor Relations<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@cortexyme.com\">ir@cortexyme.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Mental Health Infectious Diseases Health Pharmaceutical<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20210723005073\/en\/1091862\/3\/logo_large_jpg.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211; Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer\u2019s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. \u201cThere continues to be a large unmet need for coronavirus treatment. The target of COR803 is highly conserved across variants and among coronaviruses in general, therefore it is expected to address both current and future coronavirus strains, including the delta variant of SARS-CoV-2,\u201d said Casey Lynch, Cortexyme\u2019s chief executive officer, co-founder, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-517004","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211; Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer\u2019s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. \u201cThere continues to be a large unmet need for coronavirus treatment. The target of COR803 is highly conserved across variants and among coronaviruses in general, therefore it is expected to address both current and future coronavirus strains, including the delta variant of SARS-CoV-2,\u201d said Casey Lynch, Cortexyme\u2019s chief executive officer, co-founder, &hellip; Continue reading &quot;Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-23T12:03:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection\",\"datePublished\":\"2021-07-23T12:03:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/\"},\"wordCount\":837,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/\",\"name\":\"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-07-23T12:03:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/","og_locale":"en_US","og_type":"article","og_title":"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection - Market Newsdesk","og_description":"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211; Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer\u2019s disease with top-line data expected in the fourth quarter of 2021 and a growing pipeline of therapeutics for degenerative diseases, announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. \u201cThere continues to be a large unmet need for coronavirus treatment. The target of COR803 is highly conserved across variants and among coronaviruses in general, therefore it is expected to address both current and future coronavirus strains, including the delta variant of SARS-CoV-2,\u201d said Casey Lynch, Cortexyme\u2019s chief executive officer, co-founder, &hellip; Continue reading \"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-23T12:03:02+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection","datePublished":"2021-07-23T12:03:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/"},"wordCount":837,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/","name":"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-07-23T12:03:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210723005073r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cortexyme-announces-lead-3clpro-inhibitor-for-the-treatment-of-coronavirus-infection\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/517004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=517004"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/517004\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=517004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=517004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=517004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}